Why the study?
Spironolactone preserves skeletal strength in rats with aldosteronism, but the relationship of spironolactone use to fractures in humans with CHF was unknown.
Population
4,735 men with CHF at the Memphis Veterans Affairs Medical Center (167 fracture cases, 668 matched controls)
Comparison
Spironolactone use among fracture cases vs age- and race-matched control subjects without fractures
Design
Single-center matched case-control medical record review from 1999 to 2005
Answers are grounded in this paper and cite their sources.
Spironolactone was associated with lower fracture odds; hypothesis-generating and requires prospective confirmation before any practice consideration.
Objectives The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF). Background In rats with aldosteronism, spironolactone preserves skeletal strength. However, in humans, the relationship of spironolactone to fractures is not known. Methods The medical records of all male patients with CHF from 1999 to 2005 treated at the Veterans Affairs Medical Center, Memphis, Tennessee, were reviewed (n = 4,735). Odds ratios with 95% confidence intervals of having a fracture associated with spironolactone use were estimated using conditional logistic regression. Results We identified 167 cases with a single-incident fracture and matched these by age and race to 668 control subjects without fractures. After adjustment for covariates, spironolactone use was inversely associated with total fracture (odds ratio: 0.575; 95% confidence interval: 0.346 to 0.955, p = 0.0324). Conclusions The use of spironolactone is inversely associated with fractures in men with CHF.
No takes yet. Share an insight, caveat, or question.
Carbone et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: